Before a new product launches, many manufacturers need to decide if they are going to initiate a Special Access Program (SAP) (also referred to as an Early Access Program [EAP] in the US or a Compassionate Use Program [CUP] or Named Patient Program [NPP] in the EU) for their brand while they are going through regulatory approval. The…
The Canadian pharmaceutical market access environment can be quite complex at first blush. There are many agencies, organizations, and bodies to conform with along with a myriad of legislative bills and protocols to understand. This will be the first of many blogs that Impetus will create to help demystify this complex ecosystem in Canada. Our…
Impetus Digital’s market access virtual advisory board consists of 7 of the top ex-payers in Canada who are subject matter experts in pricing and market access submission processes. Our goal is to provide market access, reimbursement, pricing, and health economics managers within Canadian pharma companies quick and economical access to key insights that will help…
